Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 379

1.

The liposomal formulation of doxorubicin.

Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB.

Methods Enzymol. 2005;391:71-97.

PMID:
15721375
2.

Liposomal doxorubicin.

Tardi PG, Boman NL, Cullis PR.

J Drug Target. 1996;4(3):129-40. Review.

PMID:
8959485
3.
4.

Future directions of liposome- and immunoliposome-based cancer therapeutics.

Park JW, Benz CC, Martin FJ.

Semin Oncol. 2004 Dec;31(6 Suppl 13):196-205. Review.

PMID:
15717745
5.

Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer.

Allen TM, Cheng WW, Hare JI, Laginha KM.

Anticancer Agents Med Chem. 2006 Nov;6(6):513-23. Review.

PMID:
17100556
6.

Use of liposomes as injectable-drug delivery systems.

Ostro MJ, Cullis PR.

Am J Hosp Pharm. 1989 Aug;46(8):1576-87. Review.

PMID:
2672806
7.

Factors affecting microencapsulation of drugs in liposomes.

Kulkarni SB, Betageri GV, Singh M.

J Microencapsul. 1995 May-Jun;12(3):229-46. Review.

PMID:
7650588
8.

Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.

Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, Sparano JA, DiBella NJ, Stewart SJ, Kavanagh JJ, Gabizon AA.

Semin Oncol. 2004 Dec;31(6 Suppl 13):53-90. Review.

PMID:
15717738
9.

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles.

Waterhouse DN, Tardi PG, Mayer LD, Bally MB.

Drug Saf. 2001;24(12):903-20. Review.

PMID:
11735647
10.

Liposomal anthracyclines.

Gabizon AA.

Hematol Oncol Clin North Am. 1994 Apr;8(2):431-50. Review.

PMID:
8040147
11.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
12.

From conventional to stealth liposomes: a new frontier in cancer chemotherapy.

Cattel L, Ceruti M, Dosio F.

Tumori. 2003 May-Jun;89(3):237-49. Review.

PMID:
12908776
13.
14.

Safety aspects of pegylated liposomal doxorubicin in patients with cancer.

Alberts DS, Garcia DJ.

Drugs. 1997;54 Suppl 4:30-5. Review.

PMID:
9361959
15.

Liposomes as carriers of antitumor agents: toward a clinical reality.

Perez-Soler R.

Cancer Treat Rev. 1989 Jun;16(2):67-82. Review.

PMID:
2670206
16.

Drug delivery systems. 1. site-specific drug delivery using liposomes as carriers.

Ranade VV.

J Clin Pharmacol. 1989 Aug;29(8):685-94. Review.

PMID:
2674208
17.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
18.

Liposomal drug delivery systems: an update review.

Samad A, Sultana Y, Aqil M.

Curr Drug Deliv. 2007 Oct;4(4):297-305. Review.

PMID:
17979650
19.

Pegylated liposomal doxorubicin in ovarian cancer.

Green AE, Rose PG.

Int J Nanomedicine. 2006;1(3):229-39. Review.

20.

Pegylated liposomal doxorubicin in the treatment of breast cancer.

O'Shaughnessy JA.

Clin Breast Cancer. 2003 Dec;4(5):318-28. Review.

PMID:
14715106

Supplemental Content

Support Center